Original language | English |
---|---|
Article number | 5071 |
Number of pages | 2 |
Journal | Cancer Research |
Volume | 84 |
Issue number | 6_Supplement |
Early online date | 15 Mar 2024 |
DOIs | |
Publication status | Published - 22 Mar 2024 |
Minimal residual disease (MRD) status by peripheral blood mononuclear cells (PBMCs) and circulating tumor DNA (ctDNA) demonstrates rapid, deep, and sustained response in patients (Pts) with relapsed/refractory follicular lymphoma (R/R FL) treated with subcutaneous (SC) epcoritamab monotherapy in the pivotal phase 1/2 EPCORE™ NHL-1 trial
David Soong, Isil Altintas, John Karavitis, Kim M. Linton, Wojciech Jurczak, Catherine Thieblemont, Kevin Zhao, Edith Szafer-Glusman, Daniela Hoehn, Elena Favaro, Mariana Sacchi, Maria Jure-Kunkel
Research output: Contribution to journal › Meeting Abstract › peer-review